KEGG   DRUG: BlinatumomabHelp
Entry
D09325                      Drug                                   

Name
Blinatumomab (USAN/INN);
Blinatumomab (genetical recombination) (JAN);
Blincyto (TN)
Product
Formula
C2367H3577N649O772S19
Exact mass
54052.5286
Mol weight
54085.8484
Remark
ATC code: 
Chemical group: 
Efficacy
Antineoplastic, Anti-CD19 and CD3 antibody
  Disease
B-cell precursor acute lymphoblastic leukemia (Philadelphia chromosome-negative) [DS:H00001]
Comment
BiTE (CD19/CD3-bispecific T cell engaging)
Target
CD19 [HSA:930] [KO:K06465];
CD3 [HSA:915 916 917] [KO:K06450 K06451 K06452]
  Pathway
T cell receptor signaling pathway
B cell receptor signaling pathway
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC19 Blinatumomab
      D09325  Blinatumomab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Others
  Cellular antigens
   CD3
    Blinatumomab
     D09325  Blinatumomab (USAN/INN)
   CD19
    Blinatumomab
     D09325  Blinatumomab (USAN/INN)
Antineoplastics [br08340.html]
 D09325
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D09325
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09325
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09325
Orphan drugs in the USA [br08355.html]
 Orphan drugs in the USA
  D09325
Pharmacogenomic biomarkers in FDA drug labels [br08341.html]
 Companion diagnostics
  D09325
BRITE hierarchy
Other DBs
CAS: 
853426-35-4
PubChem: 
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system